SPA17 and ovarian cancer: Moreover, separate studies in ovarian cancer demonstrated that the expression rates of Sp17 (CT22), SSX (CT5), AKAP3 (CT82), AKAP4 (CT99), and PLAC1 (CT92) were 43%, 26%, 58%, 89%, and 21%, respectively.38, 40, 73, 77, 80